Format

Send to

Choose Destination
See comment in PubMed Commons below
Antiviral Res. 2014 Feb;102:61-9. doi: 10.1016/j.antiviral.2013.12.003. Epub 2013 Dec 13.

Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine.

Author information

1
Institute of Cancer Research, School of Life Sciences and Technology, Xi'an Jiaotong University, Xi'an 710061, China; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
2
Institute of Cancer Research, School of Life Sciences and Technology, Xi'an Jiaotong University, Xi'an 710061, China.
3
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
4
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
5
Institute of Cancer Research, School of Life Sciences and Technology, Xi'an Jiaotong University, Xi'an 710061, China. Electronic address: wangyili@mail.xjtu.edu.cn.

Abstract

Despite the success of L1 virus-like particles (VLPs) vaccines in prevention of high-risk human papillomavirus (HPV) infection and cervical cancer, extraordinary high cost for the complete vaccination has impeded widespread use of the vaccine in resource-poor countries, where cervical cancers impose greater challenge. Presentation of HPV L1 protein by attenuated pathogenic bacteria through natural infection provides a promising low-cost and convenient alternative. Here, we describe the construction and characterization of attenuated L1-expressing Shigella vaccine candidate, by fusion of L1 into the autotransporter of Shigella sonnei, IcsA, an essential virulence factor responsible for actin-based motility. The functional α domain of IcsA was replaced by codon-optimized L1 gene with independent open reading frames (ORFs) facilitated by suicide vector pJCB12. The L1 gene was stabilized in the genome of recombinant S. sonnei with protein expression and assembly of VLPs in the bacterial cytoplasm. Through conjunctival route vaccination in guinea pigs, L1-containing S. sonnei was able to elicit specific immune response to HPV16 L1 VLP as well as bacterial antigens. The results demonstrated the feasibility of the novel stratagem to develop prophylactic Shigella-HPV vaccines.

KEYWORDS:

Autotransporter; Genomic integration; Human papillomavirus vaccine; Shigella sonnei

PMID:
24333518
DOI:
10.1016/j.antiviral.2013.12.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center